Holding(s) in Company
Renalytix plc
(“Renalytix” or the “Company”)
Holding(s) in Company
LONDON and NEW YORK, 16 October 2025 – Renalytix plc (LSE: RENX) (OTCQB: RNLXY), announces that it has received a TR-1 notification from Harwood Capital LLP following the recent admission of ordinary shares and increase in the Company’s total issued share capital (RNS 8264C: $4m balance sheet improvement with bond conversion). The resulting crossing of a threshold is due to an increase in the Company’s total issued share capital, rather than any disposal or acquisition of shares. The TR-1 notification is reproduced below.
1. Issuer Details
ISIN
GB00BYWL4Y04
Issuer Name
RENALYTIX PLC
UK or Non-UK Issuer
UK
2. Reason for Notification
An event changing the breakdown of voting rights
3. Details of person subject to the notification obligation
Name
Harwood Capital LLP
City of registered office (if applicable)
Country of registered office (if applicable)
|
Name |
City of registered office |
Country of registered office |
|
Harwood Capital Management (Gibraltar) Limited |
Gibraltar |
Gibraltar |
|
Harwood Capital LLP |
London |
United Kingdom |
4. Details of the shareholder
|
Name |
City of registered office |
Country of registered office |
|
North Atlantic Smaller Companies Investment Trust Plc |
London |
United Kingdom |
|
Oryx International Growth Fund Limited |
Guernsey |
Guernsey |
|
Harwood Capital LLP |
London |
United Kingdom |
5. Date on which the threshold was crossed or reached
15-Oct-2025
6. Date on which Issuer notified
15-Oct-2025
7. Total positions of person(s) subject to the notification obligation
|
|
% of voting rights attached to shares (total of 8.A) |
% of voting rights through financial instruments (total of 8.B 1 + 8.B 2) |
Total of both in % (8.A + 8.B) |
Total number of voting rights held in issuer |
|
Resulting situation on the date on which threshold was crossed or reached |
3.903000 |
0.000000 |
3.903000 |
17061345 |
|
Position of previous notification (if applicable) |
4.411130 |
0.000000 |
4.411130 |
|
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached
8A. Voting rights attached to shares
|
Class/Type of shares ISIN code(if possible) |
Number of direct voting rights (DTR5.1) |
Number of indirect voting rights (DTR5.2.1) |
% of direct voting rights (DTR5.1) |
% of indirect voting rights (DTR5.2.1) |
|
GB00BYWL4Y04 |
11500000 |
|
2.631000 |
|
|
GB00BYWL4Y04 |
4800000 |
|
1.098000 |
|
|
GB00BYWL4Y04 |
761345 |
|
0.174000 |
|
|
Sub Total 8.A |
17061345 |
3.903000% |
||
8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))
|
Type of financial instrument |
Expiration date |
Exercise/conversion period |
Number of voting rights that may be acquired if the instrument is exercised/converted |
% of voting rights |
|
|
|
|
|
|
|
Sub Total 8.B1 |
|
|
|
|
8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))
|
Type of financial instrument |
Expiration date |
Exercise/conversion period |
Physical or cash settlement |
Number of voting rights |
% of voting rights |
|
|
|
|
|
|
|
|
Sub Total 8.B2 |
|
|
|
||
9. Information in relation to the person subject to the notification obligation
2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)
|
Ultimate controlling person |
Name of controlled undertaking |
% of voting rights if it equals or is higher than the notifiable threshold |
% of voting rights through financial instruments if it equals or is higher than the notifiable threshold |
Total of both if it equals or is higher than the notifiable threshold |
|
Christopher Harwood Bernard Mills |
North Atlantic Smaller Companies Investment Trust Plc |
2.631000 |
|
2.631000% |
|
Christopher Harwood Bernard Mills |
Oryx International Growth Fund Limited |
1.098000 |
|
1.098000% |
|
Christopher Harwood Bernard Mills |
Harwood Capital LLP |
0.174000 |
|
0.174000% |
10. In case of proxy voting
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional Information
12. Date of Completion
15/10/2025
13. Place Of Completion
London Stock Exchange
For further information, please contact:
|
Renalytix plc |
||
|
James McCullough, CEO |
Via Walbrook PR |
|
|
|
|
|
|
SP Angel Corporate Finance LLP (Nominated Adviser and Joint Broker) |
Tel: +44 (0)20 3470 0470 |
|
|
Jeff Keating / David Hignell (Corporate Finance) Vadim Alexandre (Corporate Broking) |
|
|
|
|
|
|
|
Oberon Capital (Joint Broker) |
Tel: +44 (0)20 3179 5300 |
|
|
Mike Seabrook / Nick Lovering |
|
|
|
|
|
|
|
Walbrook PR Limited |
Tel: 020 7933 8780 or [email protected] |
|
|
Paul McManus / Alice Woodings |
Mob: 07980 541 893 / 07407 804 654 |
|
About Renalytix ( www.renalytix.com )
Renalytix (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes. Renalytix has received FDA approval and Medicare reimbursement for kidneyintelX.dkd which is now offered commercially in the United States.
Unrecognized and uncontrolled kidney disease remains one of the largest barriers to controlling cost and suffering in the United States and the United Kingdom’s medical system, affecting over 14 million and 8 million people, respectively. After five years of development and clinical validation, kidneyintelX.dkd is the only FDA-approved and Medicare reimbursed prognostic tool capable of understanding a patient’s risk with kidney disease early where treatment has maximal effect. kidneyintelX.dkd is now being deployed across large physician group practices and health systems in select regions of the United States.
The over 15,000 patients that have been tested by kidneyintelX.dkd have produced a substantial body of real-world performance data. In patient populations where kidneyintelX.dkd has been deployed, a demonstrated and significant increase in diagnosis, prognosis, and treatment rates have been recorded. kidneyintelX.dkd now has full reimbursement established by Medicare, the largest insurance payer in the United States, at $950 per reportable result. kidneyintelX.dkd is also recommended for use in the international chronic kidney disease clinical guidelines (KDIGO).
KidneyIntelX is based on technology developed by Mount Sinai faculty and licensed to Renalytix AI, Inc. Mount Sinai faculty members are co-founders and equity owners in the Company. In addition, the Icahn School of Medicine at Mount Sinai has equity ownership in Renalytix. For information about the kidneyintelX.dkd test, visit kidneyintelx.com .